BLOG/🇺🇸United States··daily

Significant Contract Modifications ($10M+) — April 08, 2026

Significant Contract Modifications ($10M+)

21 total filings analysed

Executive Summary

These 21 significant contract modifications totaling $1,703,423,541 in obligations are entirely civilian (0/21 defense-related), highlighting robust federal spending in biotech R&D, IT services, and facilities support outside DOD. Dominant themes include HHS/BARDA biothreat preparedness (Shionogi $119M, Vedanta $79M) and IT modernization across Treasury/IRS (IBM $110M + $90M), VA (Salient CRGT $93M), and GSA (Mantech $77M potential $910M). Highest-conviction bullish signal is Shionogi's $119M BARDA award (up to $482M options) for antibiotics R&D through 2036, signaling multi-year biotech revenue. Key risk is zero outlays on multiple high-value awards (e.g., Shionogi $119M, Mantech $77M, Deloitte $70M), exposing execution delays amid fixed-price structures.

Tracking the trend? Catch up on the prior Significant Contract Modifications ($10M+) digest from April 07, 2026.

Investment Signals(7)

  • Shionogi $119M HHS BARDA Biotech R&D Contract(HIGH)

    Shionogi Inc secured a $119M cost-plus-fixed-fee contract (potential $482M base + options) from HHS BARDA for antibiotics targeting drug-resistant infections, with a 10-year period to 2036-03-10 under full competition.

  • Salient CRGT $93M VA IT Platform Services Delivery Order(HIGH)

    Salient CRGT won a $93M time-and-materials delivery order (potential $199M) from VA Technology Acquisition Center for technical application platforms, with $22M already outlayed since April 2025 award.

  • Mantech $77M GSA USSOUTHCOM Cyber IT Order (Potential $910M)(HIGH)

    Mantech Advanced Systems (parent Mantech International) received a $77M cost-plus-award-fee GSA delivery order for USSOUTHCOM cyber IT services, with ceiling up to $910M through potential 2032.

  • Vedanta $79M HHS BARDA Antibiotic Countermeasures R&D(HIGH)

    Vedanta Biosciences secured a $79M cost-sharing contract (potential $114M) from HHS BARDA, with $71M outlayed since 2020 for biotech R&D against antibiotic-resistant infections through 2027 (potential 2031).

  • IBM $90M Treasury IRS Modernized E-File Services(MEDIUM)

    IBM won a $90M firm-fixed-price delivery order (potential $148M) from Treasury IRS IT Operations for e-file IT services, with $51M outlayed since May 2024 through potential 2029.

  • IBM $110M Treasury Contract Terminated for Convenience(HIGH)

    IBM's $110M firm-fixed-price Treasury IRS e-file modernization order (fully outlayed) faces termination dated 3/24/2025 per executive orders, despite 2024 performance end.

  • Syncom $100M NASA Facilities Support Nearing Completion(MEDIUM)

    Syncom Space Services (Amentum subsidiary) has $100M NASA obligation with $99M outlayed for Stennis Space Center operations through June 2025.

Risk Flags(4)

  • Execution[HIGH RISK]

    Zero outlays on top awards like Shionogi $119M HHS BARDA, Mantech $77M GSA, and Deloitte $70M State Dept expose delays in biotech/IT execution.

  • Budget[MEDIUM RISK]

    SmARTRONIX $116M GSA IT order shows negative -$162k outlayed on 2018-2023 contract, signaling potential de-obligation.

  • Regulatory[HIGH RISK]

    IBM $110M Treasury contract terminated 3/24/2025 per executive orders, risking final settlement on fully outlayed funds.

  • Competition[MEDIUM RISK]

    High fixed-price risks on Quality Support $113M State visa services (SDVOSB set-aside, $0 outlayed through 2026) and ENSCO $70M DOT rail inspection.

Opportunities(4)

  • Mantech $77M GSA cyber IT order offers $910M ceiling via options for USSOUTHCOM through 2032.

  • Serco $96M PBGC engineering services delivery order with $239M potential through 2029.

  • Salient CRGT $93M VA IT platform services with $199M ceiling through potential 2030.

  • Shionogi and Vedanta HHS BARDA biotech R&D contracts ($119M + $79M obligations, up to $596M combined potential) for biothreat antibiotics.

Sector Themes(3)

  • Shionogi $119M and Vedanta $79M awards (combined $198M obligation, $596M potential) fund late-stage antibiotics development for drug-resistant pathogens through 2031-2036.

  • IT-heavy wins include Salient CRGT $93M VA, Mantech $77M GSA cyber, IBM $90M+$110M Treasury IRS, Deloitte $70M State (NAICS 541512 dominant).

  • VA awards to Salient CRGT $93M IT platforms, General Dynamics IT $65M computing, Greenbrier $61M software maintenance signal sustained IT/compute spending.

Watch List(5)

  • 👁

    {"entity"=>"Shionogi Inc", "reason"=>"$119M HHS BARDA obligation at $0 outlayed; 10-year biotech R&D potential to $482M.", "trigger"=>"outlay progress, FDA milestones, 2036-03-10 options"}

  • 👁

    {"entity"=>"Mantech International Corp", "reason"=>"$77M GSA USSOUTHCOM cyber IT with $910M ceiling, $0 outlayed.", "trigger"=>"option exercises post-2026-04-24"}

  • 👁

    {"entity"=>"IBM Corporation", "reason"=>"Dual Treasury $200M+ IRS IT orders; one terminated 3/24/2025.", "trigger"=>"termination settlement, $148M options on active order"}

  • 👁

    {"entity"=>"Salient CRGT Inc", "reason"=>"$93M VA IT order with $22M outlayed toward $199M potential.", "trigger"=>"outlay ramp, 2030-04-10 extension"}

  • 👁

    {"entity"=>"Vedanta Biosciences Inc", "reason"=>"$79M HHS BARDA with $71M outlayed; options to $114M.", "trigger"=>"remaining drawdown, 2027-01-31 vs 2031-12-31 end"}

Get daily alerts with 7 investment signals, 4 risk alerts, 4 opportunities and full AI analysis of all 21 filings

More from: Significant Contract Modifications ($10M+)

🇺🇸 More from United States

View all →